Linawise-m-5/500 tablets - Linagliptin 5mg + Metformin 500mg Tablets

LINAWISE-M 5/500 Tablets are a fixed-dose combination of Linagliptin, a DPP-4 inhibitor, and Metformin, a biguanide — formulated to provide comprehensive glycemic control in adults with Type 2 Diabetes Mellitus (T2DM).

Linagliptin (5 mg)

A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that increases levels of active incretin hormones (GLP-1 and GIP).
Enhances glucose-dependent insulin secretion and suppresses glucagon release, leading to lower fasting and postprandial blood glucose.
Minimal risk of hypoglycemia since it acts only in a glucose-dependent manner.
Hepatically cleared, thus no dose adjustment required in renal impairment.
Provides weight-neutral glucose control.

Metformin (500 mg, Sustained Release)

A Biguanide that primarily works by reducing hepatic glucose production (gluconeogenesis).
Improves peripheral glucose uptake and insulin sensitivity in muscles and adipose tissue.
Does not cause hypoglycemia or weight gain.
Exhibits favorable cardiovascular and metabolic benefits.

LINAWISE-M 5/500 Tablets are indicated for

Management of Type 2 Diabetes Mellitus in adults.
Patients inadequately controlled with Metformin monotherapy.
As an adjunct to diet and exercise to improve glycemic control.